Related Experiment Video
Updated: Jul 6, 2026
Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates
Published on: January 27, 2019
[Antibodies against Trypanosoma cruzi in intact mice and their oncoprotective effect]
Abstract:
Trypanosoma cruzi antibodies that are important in the anticancer effect of this species of Trypanosoma were first detected in 14% of the 374 examined intact mice. These background antibodies were polyclonal, i.e. they reacted with one or other of 9 genetically different T. cruzi clones and detected antigenic determinants in different structures of a Trypanosoma cell. Their spread in the population varied with animal batches; the titers were not greater than 1:40 and the level remained steady during a one-month observation. The growth of Ehrlich's adenomacarcinoma inoculated to these mice was inhibited by 1.5-2.5 times and, in some cases, terminated in total regression. The paper discusses the capacities of such antibodies in man and their inductor-commonness of the antigens of the normal intestinal microflora and the cells of the vertebrate with T. cruzi.
Insights
Naturally occurring Trypanosoma cruzi antibodies were found in mice, inhibiting tumor growth and causing regression. These findings suggest potential roles for similar antibodies in human cancer therapy.
Area of Science:
- Immunology
- Parasitology
- Oncology
Context:
- Trypanosoma cruzi infections can elicit immune responses with potential therapeutic applications.
- Pre-existing antibodies against T. cruzi were investigated for their role in cancer inhibition.
- The study examined naturally occurring antibodies in mice without deliberate T. cruzi infection.
Purpose:
- To investigate the presence and effect of naturally occurring Trypanosoma cruzi antibodies in mice.
- To determine if these antibodies contribute to the inhibition of Ehrlich's adenocarcinoma growth.
- To explore the potential implications for human cancer treatment.
Summary:
- Naturally occurring polyclonal Trypanosoma cruzi antibodies were detected in 14% of examined mice.
- These antibodies reacted with various T. cruzi clones and cell structures.
- Mice with these antibodies showed significant inhibition (1.5-2.5 times) of Ehrlich's adenocarcinoma, with some cases resulting in total tumor regression.
Impact:
- Highlights the potential of naturally occurring antibodies in cancer immunotherapy.
- Suggests a link between T. cruzi antigens and cross-reactivity with host antigens, potentially influencing autoimmune responses or therapeutic efficacy.
- Opens avenues for exploring antibody-based cancer treatments derived from parasitic infections.
